• Aclaris Therapeutics, Inc. (NASDAQ: ACRS) sees a 76.53% increase due to progress in its drug pipeline.
• Corvus Pharmaceuticals, Inc. (CRVS) experiences a 142.73% surge, attributed to promising eczema treatment results.

The stock market has recently seen notable gains across various sectors. Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has experienced a 76.53% increase in its stock price, reaching $4.62. This rise is likely due to the company's progress in its drug pipeline, particularly the Phase 1b trial for ATI-052 targeting atopic dermatitis, as highlighted by Dr. Jesse Hall, Chief Medical Officer of Aclaris.

Corvus Pharmaceuticals, Inc. (CRVS) has seen a remarkable 142.73% increase, with its stock price hitting $19.54. This surge is attributed to promising results in its eczema treatment, which has driven the stock to an eight-year high. The company's focus on immuno-oncology therapies, especially its lead product candidate, Mupadolimab, and strategic collaborations, have likely contributed to this positive market response.

RAPT Therapeutics, Inc. (RAPT) saw its stock price increase by 63.83% to $57.50. Despite an investigation by Ademi LLP into potential breaches of fiduciary duty in its transaction with GSK plc, the company's promising drug candidates, such as RPT193 and FLX475, continue to drive investor interest. These candidates are in various stages of clinical trials, contributing to the company's significant price movement.

In summary, the recent market movements highlight the dynamic nature of the stock market, with companies across different sectors experiencing rapid changes in valuations.